Coherus BioSciences (NASDAQ:CHRS – Free Report) had its price objective trimmed by Robert W. Baird from $11.00 to $9.00 in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the company. […]
Related Keywords
United States , America , Dennism Lanfear , Coherus Biosciences , Robertw Baird , Maxim Group , Blackrock Inc , C Worldwide Group Holding , Barclays Plc , Worldwide Group Holding , Coherus Biosciences Inc , Coherus Biosciences Company Profile , Marshall Wace , Barclays , Free Report , Moderate Buy , Biosciences Trading Down , Get Free Report , Street Corp , Coherus Biosciences Daily , Nasdaq Chrs , Chrs , Medical , Lower Price Target ,
comparemela.com © 2020. All Rights Reserved.